Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Primary Care Physicians Now Have Resources to Diagnose a Rare Autoimmune Disease: Relapsing Polychondritis
  • USA - English

RPASF creates a collaborative benchmark resource on relapsing polychondritis outlining the common symptoms, possible complications, diagnostic checkpoints, and key information to aid physicians and health care professionals as well as patients suffering from this rare autoimmune disease.


News provided by

RPASF

May 21, 2019, 11:00 ET

Share this article

Share toX

Share this article

Share toX

Relapsing Polychondritis (RP) Poster
Relapsing Polychondritis (RP) Poster

NEW YORK, May 21, 2019 /PRNewswire-PRWeb/ -- A primary care physician sees a patient with unexplainable symptoms: a combination of general malaise, low grade fever, redness and pain on the eyes, inflammation and pain in the ear, shortness of breath, pain and redness on the nose, skin lesions, joint pain, rib pain, hearing loss, dry cough, and wheezing. However, inflammation tests read normal; there is no diagnosable disease in the lungs; and no discernible problems with the ears. Thanks to the Relapsing Polychondritis Awareness and Support Foundation (RPASF), that doctor now has the easy-to-understand, peer-reviewed resources to know that her/his patient may have a rare autoimmune disease.

First described in 1923, relapsing polychondritis (RP) has been studied ever since, but, until recently,with limited progress. Researchers have confirmed that the disease causes the body to attack its own cartilage and can prove fatal, especially if left untreated, but there are currently no biomarkers to provide a confirmed diagnosis, nor is it known what causes flare-ups. The disease tends to be more prevalent in Caucasians and women, but it seems to affect all ethnic groups and be uncorrelated with any specific environmental factor, further complicating the diagnostic process.

Relapsing polychondritis is also a rare disease, making it unlikely that doctors will consider it, if they are even aware of it to begin with. According to Dr. Marcela Ferrada, Lawrence Shulman Scholar and relapsing polychondritis researcher at the NIH's National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the incidence is estimated to be between .71 to 3.5 per million per year. "But," she says, "I believe that this may be because RP is under-diagnosed and under-recognized. I suspect that this disease is more common than people think."

To equip physicians with the knowledge necessary to spot the disease, RPASF has created a new resource that's unique in two important ways. First, it condenses the available information on RP into succinct, memorable categories, including common symptoms, possible complications, a diagnostic checklist, and information specifically for physicians and health care professionals. For potential patients, it also provides a list of support groups.

Second, it uses information from an increasingly collaborative group of outstanding RP researchers, which is critical for a rare disease with limited literature, some of which is outdated. "Most of what you first see after you're diagnosed with RP is 'It can be fatal,'" says Rachel Wollan, an RP patient living in Indiana. "When that's pretty much all you see when you're doing research on your own, it can be pretty depressing."

Because of the difficulty of making the diagnosis, many RP sufferers go years without a diagnosis, and while they search for answers, the disease does irreparable damage to their body. However, with the new poster from RPASF, medical care professionals now have tools to better serve these patients. In the words of Dr. Joseph Ahearn, chair of the Allegheny Health Network Autoimmunity Institute, "It doesn't matter if it's a rare disease if you have it."

About Relapsing Polychondritis
Relapsing polychondritis (RP) is a systemic inflammatory disease of unknown etiology that can be fatal. The disease affects multiple organs, particularly cartilaginous structures such as the ears, nose, airway and joints as well as eyes, skin, vasculature, heart valves, and brain. For more information, visit http://bit.ly/RP_Poster.

About Race for RP
Race for RP supports research, awareness programs, and cares for those who are affected by relapsing polychondritis and related diseases. For more information, visit Race for RP's website and watch the Race for RP animation.

About RPASF
RPASF's purpose is to increase awareness about relapsing polychondritis, provide for those who are affected by RP, support research to advance a cure, and promote quality care for patients with RP. For more information, visit RPASF's website.

About AHN Autoimmunity Institute
The AHN Autoimmunity Institute is an unprecedented venture focused on advancing the diagnosis, treatment, prevention and cure of all autoimmune diseases, of which there are more than 100. The Institute's focus is on improved outcomes, increased patient satisfaction and quality of life, and decreased cost of care, through collaborative multispecialty care, cutting-edge research, advocacy and education in attacking these chronic diseases. For more information, visit http://www.ahn.org/autoimmunity-institute.

SOURCE RPASF

Related Links

http://www.polychondritis.org/

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.